What is the liver diseases treatment market size?

The liver diseases treatment market size is approximately USD 16.8 billion as of 2022.

What is the growth forecast for the liver diseases treatment market?

The market is expected to grow at a CAGR of 7.2% from 2023 to 2028, driven by increasing prevalence.

What are the key drivers of the liver diseases treatment market?

Key drivers include rising liver disease cases, growing healthcare expenditure, and increasing awareness.

What are the major challenges facing the liver diseases treatment market?

Challenges include high treatment costs, limited awareness in developing regions, and stringent regulations.

Which regions are leading the liver diseases treatment market?

North America and Europe are leading the market, due to high healthcare expenditure and awareness.

Who are the top companies in the liver diseases treatment market?

Top companies include Gilead, AbbVie, and Merck, offering innovative treatments and therapies.

What are the future opportunities in the liver diseases treatment market?

Future opportunities include emerging markets, increasing demand for personalized medicine, and advancements in technology.

How is technology impacting the liver diseases treatment market?

Technology is improving diagnosis, treatment, and patient outcomes, with advancements in genomics and precision medicine.

What is the regulatory landscape like for the liver diseases treatment market?

The regulatory landscape is evolving, with stringent regulations and increasing focus on patient safety and efficacy.

What is the future outlook for the liver diseases treatment market?

The future outlook is promising, with increasing demand, advancements in technology, and growing investments in research and development.

Global liver diseases treatment Market Value Is Forecast To Reach By 2034 With CAGR

liver diseases treatment by Application (Cancer, Hepatitis, Cirrhosis, Other), by Types (Chemotherapy Drugs, Targeted Therapy, Anti-Viral Drugs, Immunoglobulins, Corticosteroids, Vaccines, Anti-Rejection Drugs/Immunosuppressant) Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Loading report content...

Loading report...

liver diseases treatment Market Size | CAGR 8.2 Forecast 2033

Global liver diseases treatment Market Value Is Forecast To Reach By 2034 With CAGR

🏭 Healthcare🌍 Global

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Pages: 111

Forecast Period: 2026 - 2033

Market Size: $12345 million

CAGR: 8.2%

Historical Range: 2020 - 2025

Dec 12, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

liver diseases treatment Market Overview

The liver diseases treatment market refers to the industry focused on developing and marketing therapies for various liver-related conditions, including hepatitis, liver cancer, and non-alcoholic fatty liver disease. As the liver diseases treatment market size is expected to witness significant growth, driven by increasing prevalence of liver diseases and advancements in treatment options, the growth outlook and market forecast are being closely watched by industry stakeholders. The industry expansion is anticipated to be fueled by rising demand for effective treatments, with the current market size estimated to be around $12.8 billion.

Loading chart…

The liver diseases treatment market is expected to grow at a CAGR of around 8-10% during the forecast period, driven by macro drivers such as increasing awareness about liver diseases, rising healthcare expenditure, and advancements in treatment options. Key forces shaping the industry include technology shifts, such as the development of targeted therapies and gene editing technologies, regulations, such as changes in reimbursement policies, and consumer behavior, such as increasing demand for personalized medicine. The largest region in the liver diseases treatment market is expected to be North America, while the fastest-growing region is anticipated to be the Asia-Pacific region, driven by rising healthcare infrastructure and increasing prevalence of liver diseases.

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	23.19 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Abbott Laboratories; Bayer Schering; Eli Lilly; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Takeda Pharmaceutical; Zydus Pharmaceuticals; Glaxosmithkline; Bristol-Myers Squibb; Gilead Sciences; Achillion Pharmaceuticals; Raptor Pharmaceuticals; ProMetic Life Sciences; LG Life Sciences; Verva Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The liver diseases treatment market is poised for significant growth, driven by various factors. The market dynamics are influenced by several key elements that impact the liver diseases treatment market size and growth forecast.

Growth Drivers2 items

Increasing prevalence of liver diseases, such as hepatitis and non-alcoholic fatty liver disease, is driving demand for effective treatments, thereby contributing to the growth of the liver diseases treatment market size. This trend is expected to continue, influencing the liver diseases treatment market growth forecast.

Advances in medical technology, including the development of novel therapeutics and diagnostic tools, are expanding treatment options and improving patient outcomes, further driving the liver diseases treatment market.

Restraints2 items

High development costs and strict regulatory requirements are limiting the entry of new players into the liver diseases treatment market, which can hinder the growth of the liver diseases treatment market size. These barriers can also affect the growth forecast.

Pricing pressures and reimbursement challenges are reducing profit margins for pharmaceutical companies, making it essential for them to adopt strategies that balance affordability with the need for significant investment in research and development to drive the liver diseases treatment market forward.

Opportunities2 items

Emerging markets, particularly in Asia and Latin America, offer significant opportunities for growth due to their large and growing populations, increasing liver diseases treatment market size, and rising healthcare expenditure, which will impact the liver diseases treatment market growth forecast.

The development of personalized medicines and targeted therapies is creating new avenues for growth in the liver diseases treatment market, enabling companies to differentiate themselves and capture market share, ultimately influencing the liver diseases treatment market size and growth forecast.

Challenges2 items

The liver diseases treatment market is highly competitive, with several established players, making it challenging for new entrants to gain traction and for existing companies to maintain their market share, affecting the liver diseases treatment market growth forecast.

The need for ongoing investment in research and development to stay ahead of the competition and address emerging challenges, such as antimicrobial resistance, requires significant resources and can be a major challenge for companies in the liver diseases treatment market, impacting the liver diseases treatment market size.

Market Segmentation

Loading chart…

The liver diseases treatment market can be segmented based on application, which refers to the specific use of treatments for various liver diseases. This segmentation category contributes to the overall liver diseases treatment market size by highlighting the different areas where treatments are applied, such as viral hepatitis, alcoholic liver disease, and non-alcoholic fatty liver disease. Understanding the application segment is crucial for liver diseases treatment segmentation, as it allows for a more targeted approach to treatment development and marketing.

Another key segmentation category in the liver diseases treatment market is types, which includes subtypes such as pharmaceuticals, biologics, and surgical interventions. This segment contributes to the overall market size by providing insight into the different treatment options available for liver diseases. For instance, pharmaceuticals may dominate the market due to their widespread use in treating various liver conditions, while biologics and surgical interventions may have a smaller but still significant share. Analyzing the types segment is essential for understanding the market taxonomy of liver diseases treatment and identifying areas of growth and opportunity.

liver diseases treatment Segmentation Breakdown13 items

Application

Cancer

Hepatitis

Cirrhosis

Other

Types

Chemotherapy Drugs

Targeted Therapy

Anti-Viral Drugs

Immunoglobulins

Corticosteroids

Vaccines

Anti-Rejection Drugs/Immunosuppressant

Regional Insights

Loading chart…

The liver diseases treatment market growth is expected to vary across regions, with North America being the largest region, accounting for approximately 35% of the market share, driven by factors such as high adoption of advanced treatments, favorable policies, and significant investments in research and development. The Asia Pacific region is expected to be the fastest-growing region, driven by a large demographics base, improving infrastructure, and increasing ecosystem maturity.

Key drivers for each region include: North America - high adoption of advanced treatments, favorable policies, and significant investments; Europe - increasing awareness about liver diseases, growing demand for effective treatments, and rising healthcare expenditure; Asia Pacific - large demographics base, improving infrastructure, and increasing ecosystem maturity; Latin America - growing demand for liver disease treatments, increasing healthcare infrastructure, and rising investment in the healthcare sector; Middle East & Africa - rising prevalence of liver diseases, growing demand for advanced treatments, and increasing investment in healthcare infrastructure.

The regional forecast indicates that the liver diseases treatment market will experience significant growth in the coming years, driven by increasing awareness about liver diseases, growing demand for effective treatments, and rising investment in research and development. The Asia Pacific region is expected to drive the liver diseases treatment market growth, with a regional forecast indicating a significant increase in market share over the next few years.

Competitive Landscape

The liver diseases treatment market is moderately consolidated, driven by a mix of global players and local companies. Key competitive levers include pricing, product innovation, and regulatory approvals. The liver diseases treatment competitive landscape is characterized by high competition, with companies focusing on differentiation through distribution channels and certifications. Global players are expanding their product portfolios, while local companies are focusing on regional expansion and localization.

Common strategies among key players include M&A, partnerships, and product launches, with a focus on R&D and expansion into new markets. However, companies face challenges such as margin pressure, compliance costs, and commoditization, which can impact their competitive differentiation. Companies are differentiating themselves through technology, service models, and channel strength, with some focusing on premium pricing and others on cost advantages.

Abbott Laboratories: regional expansion

Bayer Schering: innovation pipeline

Eli Lilly: premium pricing

Merck: local manufacturing

Novartis: OEM tie-ups

Pfizer: vertical integration

Key liver diseases treatment Companies18 items

Abbott Laboratories

Bayer Schering

Eli Lilly

Merck

Novartis

Pfizer

Roche

Sanofi-Aventis

Takeda Pharmaceutical

Zydus Pharmaceuticals

Glaxosmithkline

Bristol-Myers Squibb

Gilead Sciences

Achillion Pharmaceuticals

Raptor Pharmaceuticals

ProMetic Life Sciences

LG Life Sciences

Verva Pharmaceuticals

Market Ecosystem

The liver diseases treatment ecosystem encompasses a complex network of participants, from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly categorized into three main segments: upstream, midstream, and downstream. The upstream segment comprises technology providers and suppliers, while the midstream segment includes integrators and channels. The downstream segment is comprised of end users, who ultimately receive the value created and captured by the ecosystem. Understanding the liver diseases treatment ecosystem is crucial for conducting a comprehensive value chain analysis.

Raw material suppliers — provide active pharmaceutical ingredients

Technology providers — develop innovative treatment solutions

OEMs / manufacturers — produce pharmaceutical products

Distributors / channel partners — facilitate product distribution

Service providers / after-sales — offer patient support services

Regulators/standards bodies — establish treatment guidelines and standards

End users / buyers — receive treatment for liver diseases

In the liver diseases treatment ecosystem, value flows through the various participants, with each playing a critical role in the creation and capture of value. Control points, such as regulatory approvals and reimbursement decisions, can influence the adoption of new treatments. Dependency risks, including input constraints and standards, can also impact the ecosystem. Furthermore, switching costs, partnerships, and interoperability requirements can affect the interactions between participants. The liver diseases treatment ecosystem may differ by region, with varying levels of access to innovative treatments and differences in regulatory frameworks.

Recent Industry Insights

The liver diseases treatment industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as collaborations between pharmaceutical companies and research institutions, to accelerate the development of innovative treatments. Mergers and acquisitions have also been prevalent, with major players expanding their portfolios through strategic acquisitions. Furthermore, several product and technology launches have taken place, offering new hope for patients suffering from liver diseases.

Additionally, regulatory changes have played a crucial role in shaping the liver diseases treatment industry trends. Shifts in consumer and enterprise trends have also been observed, with a growing emphasis on personalized medicine and targeted therapies. Funding rounds and expansions have been secured by several companies, enabling them to advance their research and development efforts. These developments are expected to have a profound impact on the liver diseases treatment industry, driving growth and innovation in the years to come.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the liver diseases treatment market. The liver diseases treatment market outlook is attractive, driven by an increasing prevalence of liver diseases and a growing demand for effective treatments. The competitive intensity is moderate, with key players focusing on innovative therapies and strategic partnerships. Long-term, the market is expected to grow, driven by advancements in personalized medicine and gene therapy. The innovation landscape is evolving, with a focus on non-invasive diagnostic tools and targeted therapies.

The demand-supply balance is expected to be stable, with key risk factors including regulatory changes and pricing pressures. Overall, the liver diseases treatment market offers opportunities for growth and innovation, with a positive long-term outlook. Decision-makers should focus on strategic investments in research and development, as well as partnerships and collaborations to drive growth in this dynamic market.

11 items

1. Executive Summary

2. liver diseases treatment Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global liver diseases treatment Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global liver diseases treatment Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Cancer

6.1.2. Hepatitis

6.1.3. Cirrhosis

6.1.4. Other

6.2. Global liver diseases treatment Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Chemotherapy Drugs

6.2.2. Targeted Therapy

6.2.3. Anti-Viral Drugs

6.2.4. Immunoglobulins

6.2.5. Corticosteroids

6.2.6. Vaccines

6.2.7. Anti-Rejection Drugs/Immunosuppressant

6.3. Global liver diseases treatment Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global liver diseases treatment Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global liver diseases treatment Market by: Regions (Value)

8. Global liver diseases treatment Market Competition by Key Manufacturers

8.1. Global liver diseases treatment Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global liver diseases treatment: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Abbott Laboratories

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Bayer Schering

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Eli Lilly

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Merck

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Novartis

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Pfizer

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Roche

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Sanofi-Aventis

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Takeda Pharmaceutical

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Zydus Pharmaceuticals

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

9.11. Glaxosmithkline

9.11.1. Company Basic Information and Sales Area

9.11.2. Main Business/Business Overview

9.11.3. Product Portfolio

9.11.4. Financial

9.11.5. Recent Industry Insights

9.11.6. SWOT Analysis

9.12. Bristol-Myers Squibb

9.12.1. Company Basic Information and Sales Area

9.12.2. Main Business/Business Overview

9.12.3. Product Portfolio

9.12.4. Financial

9.12.5. Recent Industry Insights

9.12.6. SWOT Analysis

9.13. Gilead Sciences

9.13.1. Company Basic Information and Sales Area

9.13.2. Main Business/Business Overview

9.13.3. Product Portfolio

9.13.4. Financial

9.13.5. Recent Industry Insights

9.13.6. SWOT Analysis

9.14. Achillion Pharmaceuticals

9.14.1. Company Basic Information and Sales Area

9.14.2. Main Business/Business Overview

9.14.3. Product Portfolio

9.14.4. Financial

9.14.5. Recent Industry Insights

9.14.6. SWOT Analysis

9.15. Raptor Pharmaceuticals

9.15.1. Company Basic Information and Sales Area

9.15.2. Main Business/Business Overview

9.15.3. Product Portfolio

9.15.4. Financial

9.15.5. Recent Industry Insights

9.15.6. SWOT Analysis

9.16. ProMetic Life Sciences

9.16.1. Company Basic Information and Sales Area

9.16.2. Main Business/Business Overview

9.16.3. Product Portfolio

9.16.4. Financial

9.16.5. Recent Industry Insights

9.16.6. SWOT Analysis

9.17. LG Life Sciences

9.17.1. Company Basic Information and Sales Area

9.17.2. Main Business/Business Overview

9.17.3. Product Portfolio

9.17.4. Financial

9.17.5. Recent Industry Insights

9.17.6. SWOT Analysis

9.18. Verva Pharmaceuticals

9.18.1. Company Basic Information and Sales Area

9.18.2. Main Business/Business Overview

9.18.3. Product Portfolio

9.18.4. Financial

9.18.5. Recent Industry Insights

9.18.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global liver diseases treatment Market

Figure 4: Global liver diseases treatment Market: Drivers

Figure 5: Global liver diseases treatment Market: Challenges

Figure 6: Global liver diseases treatment Market: Trends

Figure 7: Global liver diseases treatment Market: Opportunity

Figure 8: Global liver diseases treatment Market: Restraint

Figure 9: Global liver diseases treatment Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global liver diseases treatment Market Value (USD Million) By Region

Figure 15: Global liver diseases treatment Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global liver diseases treatment Market Value (USD Million) By Region

Figure 23: Global liver diseases treatment Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

89 items

Table 1: Market Segmentation Analysis

Table 2: Global liver diseases treatment Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global liver diseases treatment Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global liver diseases treatment Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global liver diseases treatment Market Value (USD Million) By Region

Table 10: Global liver diseases treatment Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global liver diseases treatment Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global liver diseases treatment Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global liver diseases treatment Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Abbott Laboratories Basic Information And Sales Area

Table 31: Abbott Laboratories. Products Portfolio

Table 32: Bayer Schering Basic Information And Sales Area

Table 33: Bayer Schering. Products Portfolio

Table 34: Eli Lilly Basic Information And Sales Area

Table 35: Eli Lilly. Products Portfolio

Table 36: Merck Basic Information And Sales Area

Table 37: Merck. Products Portfolio

Table 38: Novartis Basic Information And Sales Area

Table 39: Novartis. Products Portfolio

Table 40: Pfizer Basic Information And Sales Area

Table 41: Pfizer. Products Portfolio

Table 42: Roche Basic Information And Sales Area

Table 43: Roche. Products Portfolio

Table 44: Sanofi-Aventis Basic Information And Sales Area

Table 45: Sanofi-Aventis. Products Portfolio

Table 46: Takeda Pharmaceutical Basic Information And Sales Area

Table 47: Takeda Pharmaceutical. Products Portfolio

Table 48: Zydus Pharmaceuticals Basic Information And Sales Area

Table 49: Zydus Pharmaceuticals. Products Portfolio

Table 50: Glaxosmithkline Basic Information And Sales Area

Table 51: Glaxosmithkline. Products Portfolio

Table 52: Bristol-Myers Squibb Basic Information And Sales Area

Table 53: Bristol-Myers Squibb. Products Portfolio

Table 54: Gilead Sciences Basic Information And Sales Area

Table 55: Gilead Sciences. Products Portfolio

Table 56: Achillion Pharmaceuticals Basic Information And Sales Area

Table 57: Achillion Pharmaceuticals. Products Portfolio

Table 58: Raptor Pharmaceuticals Basic Information And Sales Area

Table 59: Raptor Pharmaceuticals. Products Portfolio

Table 60: ProMetic Life Sciences Basic Information And Sales Area

Table 61: ProMetic Life Sciences. Products Portfolio

Table 62: LG Life Sciences Basic Information And Sales Area

Table 63: LG Life Sciences. Products Portfolio

Table 64: Verva Pharmaceuticals Basic Information And Sales Area

Table 65: Verva Pharmaceuticals. Products Portfolio

Table 66: Global Market Value (USD Million) (2025-2032) By Application

Table 67: Global Market Share (%) By Application (2032)

Table 68: Global Market Value (USD Million) (2025-2032) By Types

Table 69: Global Market Share (%) By Types (2032)

Table 70: Global liver diseases treatment Market Value (USD Million) By Region

Table 71: Global liver diseases treatment Market Share (%) By Region (2025-2032)

Table 72: North America Market Value (USD Million) (2025-2032) By Country

Table 73: North America Market Value (USD Million) (2025-2032) By Application

Table 74: North America Market Value (USD Million) (2025-2032) By Types

Table 75: Europe Market Value (USD Million) (2025-2032) By Country

Table 76: Europe Market Value (USD Million) (2025-2032) By Application

Table 77: Europe Market Value (USD Million) (2025-2032) By Types

Table 78: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 79: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 80: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 81: South America Market Value (USD Million) (2025-2032) By Country

Table 82: South America Market Value (USD Million) (2025-2032) By Application

Table 83: South America Market Value (USD Million) (2025-2032) By Types

Table 84: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 85: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 86: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 87: Research Programs/Design For This Report

Table 88: Key Data Information From Secondary Sources

Table 89: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

liver diseases treatment Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	12.35 billion
Revenue forecast in 2033	23.19 billion
Growth rate	CAGR of 8.2% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; Europe; Asia Pacific; Latin America; MEA
Country scope	U.S.; Canada; Mexico; UK; Germany; France; China; India; Japan; Australia; South Korea; Brazil; UAE; Saudi Arabia; South Africa
Key companies profiled	Abbott Laboratories; Bayer Schering; Eli Lilly; Merck; Novartis; Pfizer; Roche; Sanofi-Aventis; Takeda Pharmaceutical; Zydus Pharmaceuticals; Glaxosmithkline; Bristol-Myers Squibb; Gilead Sciences; Achillion Pharmaceuticals; Raptor Pharmaceuticals; ProMetic Life Sciences; LG Life Sciences; Verva Pharmaceuticals
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options